Webcast – Oncopeptides rescinds voluntary withdrawal of Pepaxto
January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US. Investors, financial analysts and media were invited to participate in a webcast with a Q&A session on January 24, 2022.
The event was hosted by CEO, Jakob Lindberg and CMO, Klaas Bakker. The presentation was held in English. See the presentation in PDF below
The webcast was recorded and can be seen via https://tv.streamfabriken.com/press-conference-jan-2022